2019 Annual Meeting | C76 - Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions

Sunday 05/05/19
03:30 PM - 05:30 PM EDT Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
Michael D. Geschwind, MD, PhD, FAAN
Aging, Dementia, and Behavioral Neurology
Participants should be familiar with the differential diagnosis of prion and antibody-mediated causes of RPD and the clinical presentation and evaluation of the more common conditions.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Intermediate
Advanced Practice Provider
General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider
Case-based, Interactive, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 03:35 PM EDT Speaker Introduction
Michael D. Geschwind, MD, PhD, FAAN
03:35 PM - 04:25 PM EDT Speaker Infections as Rapidly Progressive Dementia
Allen J. Aksamit, Jr., MD, FAAN
04:25 PM - 05:15 PM EDT Speaker Autoimmune Causes of Rapidly Progressive Dementia
Jeffrey M. Gelfand, MD, MAS, FAAN
05:15 PM - 05:30 PM EDT Speaker Questions and Answers
05:30 PM - 06:00 PM EDT Discussion Continuing the Conversation
Faculty Disclosures
Michael D. Geschwind, MD, PhD, FAAN Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Allen J. Aksamit, Jr., MD, FAAN Dr. Aksamit has nothing to disclose.
Jeffrey M. Gelfand, MD, MAS, FAAN Dr. Gelfand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.